🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

CLArithromycin Versus AZIthromycin in the Treatment of Mycobacterium Avium Complex (MAC) Lung Infections

RecruitingPhase 3Ages 18 Years - anyAllCentre Hospitalier Universitaire, Amiens
NCT03236987 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

MAC lung infections are a growing public health problem. The ATS / IDSA 2007 guidelines for the treatment of these non-tuberculous mycobacterial infections recommend the use of a macrolide or azalide (clarithromycin or azithromycin), rifampicin or rifabutin and ethambutol. For MAC disseminated infections, several studies have compared combinations containing clarithromycin or azithromycin and found no significant difference in efficacy. No randomized controlled trials have been performed for pulmonary infections to compare clarithromycin and azithromycin in terms of efficacy. Clarithromycin is often used as a first-line treatment in France, but its tolerance is often poor, particularly in terms of risk of hepatitis, metallic taste in the mouth, nausea or vomiting, and it interacts with many drugs via cytochrome p450 . In particular, it increases the toxicity of rifabutin, in particular

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * patients 18 years of age or older * having a positive Mycobacterium avium complex sample showing the ATS / IDSA infection criteria and requiring treatment * ATS / IDSA infection criteria combine clinico-radiological criteria, associated with microbiological criteria * the exclusion of any other diagnosis on the thoracic CT, fibroscopy and bacteriological samples Exclusion Criteria: * Known hypersensitivity to one of the study molecules (rifampicin, ethambutol, azithromycin, clarithromycin) * Relapse of an MAC infection, * Strain resistant to macrolides, based on genotyping susceptibility testing (genotyping susceptibility testing must be done before inclusion) * Treatment that interacts with cytochrome p450 that can not be replaced by another therapeutic, * HIV serology 1 and 2, * Renal insufficiency with creatinine clearance less than 30 ml / min, * Pregnancy and breast feeding, * Contra-indication to one of the antibiotics, * Impossibility to follow the protocol due in particular to drug addiction according to the investigator, * Limited life expectancy, less than 6 months, * Patient already participating in a clinical trial on a medical treatment or a therapeutic strategy for non-tuberculous mycobacteria.
💊

What it tests

  • Clarithromycin 1000 MG
  • Azithromycin 250 mg
  • Rifampicin
  • Ethambutol
📍

Where

3 sites
CHU Amiens Picardie
Amiens, France
CHU Angers
Angers, France
Saint Joseph Hospital
Marseille, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy